1.Ma, XX, et al. Novel type of staphylococcal cassette chromosome mec identified in community-acquired methicillin-resistant Staphylococcus aureus strains. Antimicrobial Agents and Chemotherapy 2002; 46: 1147–1152.
2.Young, DM, et al. An epidemic of methicillin-resistant Staphylococcus aureus soft tissue infections among medically underserved patients. Archives of Surgery 2004; 139: 947–953.
3.Saravolatz, LD, Pohlod, DJ, Arking, LM. Community-acquired methicillin-resistant Staphylococcus aureus infections: a new source for nosocomial outbreaks. Annals of Internal Medicine 1982; 97: 325–329.
4.Miller, L, et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. New England Journal of Medicine 2005; 352: 1445–1453.
6.Deurenberg, RH, et al. The molecular evolution of methicillin-resistant Staphylococcus aureus. Clinical Microbiology and Infection 2007; 13: 222–235.
7.Kowalski, TJ, Berbari, EF, Osmon, DR. Epidemiology, treatment, and prevention of community-acquired methicillin-resistant Staphylococcus aureus infections. Mayo Clinic Proceedings 2005; 80: 1201–1208.
8.Huang, H, et al. Injecting drug use and community-associated methicillin-resistant Staphylococcus aureus infection. Diagnostic Microbiology and Infectious Diseases 2008; 60: 347–350.
9.Saravolatz, LD, et al. Methicillin-resistant Staphylococcus aureus. Epidemiologic observations during a community-acquired outbreak. Annals of Internal Medicine 1982; 1: 11–16.
10.King, MD, et al. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Annals of Internal Medicine 2006; 144: 309–317.
11.Shannon, K, et al. The impact of unregulated single room occupancy hotels on the health status of illicit drug users in Vancouver. International Journal of Drug Policy 2006; 17: 107–114.
12.Nelson, KE, Masters Williams, CF. Infectious Disease Epidemiology: Theory and Practice, 2nd edn. Sudbury, MA: Jones & Bartlett Publishers, 2007.
13.Huang, H, et al. Comparisons of community-associated methicillin-resistant Staphylococcus aureus (MRSA) and hospital-associated MSRA infections in Sacramento, California. Journal of Clinical Microbiology 2006; 44: 2423–2427.
14.Bradley, J, et al. Anti-infective research and development – problems, challenges, and solutions. Lancet Infectious Diseases 7: 68–78.
15.Wood, E, et al. Methodology for evaluating Insite: Canada's first medically supervised safer injection facility for injection drug users. Harm Reduction Journal 2004; 1(1): 9.
16.Costa, A, et al. Rapid detection of mecA and nuc genes in staphylococci by real-time multiplex polymerase chain reaction. Diagnostic Microbiology and Infectious Disease 2005; 51: 13–17.
17.Lina, G, et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clinical Infectious Diseases 1999; 29: 1128–1132.
18.Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Supplement M100-S16. Wayne, PA: Clinical and Laboratory Standards Institute; 2006.
19.Allison, DC, et al. Microbiology of upper extremity soft tissue abscesses in injecting drug abusers. Clinical Orthopaedics and Related Research 2007; 461: 9–13.
20.Brown, PD, Ebright, JR. Skin and soft tissue infections in injection drug users. Current Infectious Disease Reports 2002; 4: 415–419.
21.Talan, DA, Summamen, PH, Finegold, SM. Ampicillin/sulbactam and cefoxitin in the treatment of cutaneous and other soft-tissue abscesses in patients with or without histories of injection drug abuse. Clinical Infectious Diseases 2000; 31: 464–471.
22.Moran, GJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. New England Journal of Medicine 2006; 355: 666–674.
23.Ebright, JR, Pieper, B. Skin and soft tissue infections in injection drug users. Infectious Disease Clinics of North America 2002; 16: 697–712.
24.Rajendran, PM, et al. Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community acquired methicillin-resistant Staphylococcus aureus infection. Antimicrobial Agents and Chemotherapy 2007; 51: 4044–4048.
25.Lloyd-Smith, E, et al. Prevalence and correlates of abscesses among a cohort of injection drug users. Harm Reduction Journal 2005; 2: 24.
26.Lloyd-Smith, E, et al. Incidence and determinants of initiation into cocaine injection and correlates of frequent cocaine injectors. Drug and Alcohol Dependence 2008; 99: 176–182.
27.Topp, L, et al. Prevalence and predictors of injecting-related injury and disease among clients of Australia's needle and syringe programs. Australia and New Zealand Journal of Public Health 2008; 32: 34–37.
28.Hope, V, et al. Frequency, factors and costs associated with injection site infections: findings from a national multi-site survey of injecting drug users in England. BMC Infectious Diseases 2008; 8: 120.